WSI "IntroBioPharma to Launch Generic New Product with Improved Formulation... Expecting Additional Sales of 10 Billion KRW"

Introbiopharma, a pharmaceutical research and development and manufacturing subsidiary of WSI, is expected to generate additional annual sales of over 10 billion KRW through the launch of various new generic products.

On the 18th, WSI announced that Introbiopharma plans to launch three generic drugs in 2025. WSI currently holds a 67% stake in Introbiopharma.

Next year, Introbiopharma will sequentially release ▲antiepileptic drugs (for prevention and treatment of seizures such as epilepsy) 'Topimed Extended-Release Tablets in 2 dosages' ▲colonoscopy pre-treatment agent 'EasyPang Tablets' ▲hypertension and hyperlipidemia treatment 'Istarplus Tablets in 4 dosages.'

Topimed Extended-Release Tablets 50 milligrams (mg) is the first generic extended-release formulation of topiramate and is scheduled for release in March next year. The 25 mg dosage aims to obtain approval from the Ministry of Food and Drug Safety (MFDS) within this year and be launched in the first quarter of 2025. This product significantly improves ease of administration by changing from the existing capsule form to a smaller film-coated tablet form.

EasyPang Tablets are tablet-type bowel cleansing agents taken before colonoscopy. Compared to existing products, the number of tablets to be taken has been reduced from 28 to 24, enhancing patient convenience. The MFDS approval application was completed in October this year, with approval expected in the first half of next year.

Istarplus Tablets are the first domestic triple combination drug containing telmisartan, amlodipine besylate, and rosuvastatin calcium. By applying Introbiopharma’s patented technology, the product improves hygroscopicity (the property of absorbing moisture from the air and changing its characteristics), enabling bulk packaging (bottle packaging). Approval is expected to be completed in the first quarter of 2025, with plans for reimbursement listing and launch in the third quarter.

A WSI official stated, "Through the launch of various generic new products by Introbiopharma, we will achieve substantial external growth," adding, "Starting with approximately 3 billion KRW in additional sales next year, it will be possible to secure additional sales of around 10 billion KRW by 2027."

Meanwhile, Introbiopharma is a leading small and medium-sized pharmaceutical company specializing in drug formulation research and formulation changes. In June, WSI acquired a 67% stake in Introbiopharma for about 18.8 billion KRW.